TransUnion and Socially Determined Partner to Improve Health Outcomes By Using SDOH Data & Analytics

Partnership will help healthcare stakeholders visualize social risk and create better outcomes for communities and organizations

CHICAGO, Dec. 15, 2020 (GLOBE NEWSWIRE) — With over 80% of an individual’s health outcome driven by economic and social conditions1, TransUnion Healthcare (NYSE:TRU) announced today an investment in and commercial partnership with Socially Determined, the social risk analytics company. Together, the two companies will focus on leveraging Social Determinants of Health (SDOH) and clinical and claims data to provide healthcare stakeholders with social risk intelligence about the individuals and communities they serve. In turn, organizations can improve the health and well-being of people at scale.

SDOH are the economic and social conditions that impact health, such as housing instability and homelessness, food insecurity, lack of transportation, low education, interpersonal violence, social isolation, unemployment and financial stress.

The partnership strengthens the power of Socially Determined’s SocialScape® platform by bringing it together with TransUnion Healthcare’s data assets and information on individual identities. This combination helps create a more complete view of social risk factors and their impact at the community and individual level. Through advanced analytics that quantify social risk and impact, SocialScape helps identify opportunities for organizations to match high-value, targeted interventions for their populations, leading to enhanced prevention, treatment and adherence strategies at a lower cost for all.

“Effective use of SDOH by healthcare stakeholders is one of the keys to improving a person’s wellness and lowering costs which is especially critical in light of amplified, existing disparities due to the COVID-19 pandemic,” said James Bohnsack, senior vice president & chief strategy officer of TransUnion Healthcare. “TransUnion’s comprehensive data assets, accurate insights and industry expertise help healthcare payers better predict member and population risk. This partnership demonstrates how information can be used in powerful and positive ways to help the healthcare ecosystem better understand and make good decisions about communities and individuals.”

By combining and analyzing vast amounts of social and clinical data through a scalable, cloud-based platform, SocialScape® quantifies and visualizes socioeconomic insecurities and impacts. It provides powerful risk metrics that enable organizations to understand the many facets of social risk and — more importantly — how those social risks impact their business and the communities they serve.

Through the use of social risk intelligence combined with clinical data (healthcare claims and/or medical records), TransUnion Healthcare and Socially Determined will help health insurance companies, pharmaceutical companies, hospitals and health systems as well as other stakeholders align resources to improve the health and wellness of populations with the greatest need by helping remove barriers to care.

The partnership comes at a time when the COVID-19 pandemic has exacerbated the health, economic and financial challenges impacting patient populations and healthcare organizations, particularly for people of color and those with higher social risk. In addition, TransUnion’s most recent Financial Hardship Study underscores the financial effects of the pandemic, finding over half of consumers surveyed (57%) have been impacted financially by COVID-19, with a higher percentage of these respondents identifying as people of color.

“There is a great need for SDOH insights in the market, but most organizations are not in a position to leverage the data properly,” said Trenor Williams, MD, CEO and co-founder of Socially Determined. “While the impact that SDOH has on outcomes is well understood, organizations in the healthcare industry are simply not equipped to analyze social risk data alongside health records or claims data. This requires an entirely new skillset that our company was built to address. With the knowledge and depth of data assets that TransUnion brings to the table, our ability to provide clear and actionable intelligence is now much stronger.”

For additional information on how SDOH data can meaningfully inform and allow for more effective problem-solving strategies, the two companies presented a webinar on December 10, 2020. Healthcare leaders interested in learning more can access a recording of the webinar here.


About TransUnion (NYSE: TRU)

TransUnion is a global information and insights company that makes trust possible in the modern economy. We do this by providing a comprehensive picture of each person so they can be reliably and safely represented in the marketplace. As a result, businesses and consumers can transact with confidence and achieve great things. We call this Information for Good®.

TransUnion Healthcare, a wholly owned subsidiary of TransUnion, makes mutual trust possible between patients, providers, and payers by helping them navigate payment uncertainty. Our Revenue Protection® solutions leverage comprehensive data, accurate insights and industry expertise to engage patients early, ensure earned revenue gets paid and optimize payment strategies. TransUnion Healthcare helps over 1,850 hospitals and 550,000 physicians collectively recover more than $1.2 billion annually in revenue.

A leading presence in more than 30 countries across five continents, TransUnion provides solutions that help create economic opportunity, great experiences and personal empowerment for hundreds of millions of people.

About Socially Determined

Socially Determined is the social risk analytics company for organizations committed to addressing the Social Determinants of Health (SDOH). The company’s flagship platform SocialScape® quantifies social risk factors and analyzes the impact of these factors on health and business metrics. The company’s team of social risk experts provides advisory services to translate these insights into actionable solutions with measurable benefits.

Socially Determined is headquartered in Washington, DC and operates a second office in Blacksburg, VA. For more information, follow Socially Determined on Twitter (@SocDetermined) or LinkedIn (, or visit

Contact  Dave Blumberg
E-mail  [email protected]
Telephone 312-972-6646


Brixton Metals Significantly Increases the Number of Cu-Au Targets at its Thorn Project

81 rock samples return over 1 g/t Au and 68 rock samples return over 1% Cu

VANCOUVER, British Columbia, Dec. 15, 2020 (GLOBE NEWSWIRE) — Brixton Metals Corporation (“Brixton” or the “Company“) (TSXV: BBB) (OTCQB: BBBXF) is pleased to provide its rock and soil geochemistry results summary from the 2020 season on its vast 2,594 square kilometer Thorn Cu-Au-Ag Project. A total of 1473 rock samples and 5588 soil samples were collected throughout the Thorn Project.

Highlights from 2020 Rock and Soil Geochemistry

  • 81 rock samples returned greater than 1 g/t Au and 5 samples were greater than 31 g/t Au
  • 68 rock samples returned greater than 1% Cu and 4 were greater than 5% Cu
  • 38 rock samples returned greater than 100 g/t Ag and 6 were greater than 1000 g/t Ag
  • 1057 soils were above 30 ppb Au, 263 were above 100 ppb Au and 45 were above 500 ppb Au
  • 2298 soils were above 100 ppm Cu, 148 were above 500 ppm and 40 were above 1000 ppm Cu

Chairman and CEO of Brixton Metals, Gary R. Thompson stated, “The push for more geochemical work at the Thorn Project has been a huge success this year. The 2020 field season, plus this past winter geochem data mining from 150 historical assessment reports of 10,524 soils and 3200 rocks and strategic mineral claim acquisitions, generated 6 new large scale copper-gold targets. The new total number of copper-gold targets at the Thorn Project now stands at 9, significantly increasing the probability of making a major discovery along its 75-80km of favourable geology.”

Mr. Thompson continued, “At the end of 2020, Brixton finds itself in the best position, both financially and from a project perspective than it has ever been in. Brixton is expected to finish the year with CAD$9 million in cash, a strong partner in High Power Exploration advancing its Hog Heaven Project, an active drill program at Langis pursuing a maiden resource and nine targets with potential to yield a major discovery at Thorn. Looking ahead to 2021, we plan to continue advancing each of the targets at Thorn with additional geochemical work, new geophysical work and drilling where warranted.”

The highest 20 gold-in-rock samples are listed in Table 1 below. The highest gold value from the 1473 rocks samples was collected from the Outlaw West Target which returned 68.8 g/t Au. The target with the greatest number of high-grade gold samples was the Trapper Target which had ten of the Top 20 gold-in-rock samples and ranged from 6.0 g/t Au to 47.0 g/t Au. The Camp Creek Target had five in the Top 20 gold-in-rock ranging from 6.0 g/t Au to 14.1 g/t Au.

The highest copper-in-rock sample was 7.2% Cu and came from the Camp Creek Target which also had 5 samples in the Top 20 for high-grade copper samples ranging from 4.5 To 7.2% Cu. Three targets namely Camp Creek, Metla and East Target had 5 samples in the Top 20 for high-grade copper samples, see Table 1 below.

The highest silver-in-rock grade was 2890 g/t Ag which came from the Outlaw Target. The Camp Creek Target had by far the most high-grade silver hits, returning 14 of the Top 20 high-grade silver samples ranging from 135.0 g/t Ag to 1890 g/t Ag.

Click here for link to Table 1. A Summary of Results of Rocks 2020:

The overall gold-in-rock samples are summarized in Table 2 below. The Trapper Target returned the greatest number of gold samples in all four grade categories: 1 g/t, 5 g/t, 10 g/t and 31 g/t Au. Eighty-one rock samples returned greater that 1 g/t Au. Twenty-one rocks samples were greater than 5 g/t Au. Twelve rocks samples were greater than 10 g/t Au and 5 rock samples were greater than 31 g/t Au. The Trapper Target had 26 samples greater that 1 g/t Au, 10 rock samples greater than 5 g/t Au, 6 samples greater than 10 g/t Au including 4 samples greater than 31.0 g/t Au with the high of 47 g/t Au.

The overall copper-in-rock values are summarized in Table 2 below. Sixty-eight rock samples returned greater than 1% Cu with the highest copper value of 7.2% coming from the Camp Creek Target. Twenty-nine of the 68 sample greater that 1% Cu were from the Metla Target. The Metla Target had 11 samples that were over 2% Cu out of the 31 samples over 2% Cu. Four samples returned over 4% Cu, 2 from Camp Creek, 1 from the East Target and 1 from the West Trapper Target.

The overall silver-in-rock values are summarized in Table 2. Thirty-eight rock samples were greater than 100 g/t Ag and nineteen of these came from the Camp Creek Target. Seventeen rock samples were greater that 250 g/t Ag and ten of these came from the Camp Creek Target. Ten rock samples were greater than 500 g/t Ag with six of these coming from the Camp Creek target. Six rock samples were greater than 1000 g/t Ag with four coming from the Camp Creek Target.

Click here for link to Table 2. Rock Sample Statistics 2020:

During the 2020 field season 5588 soil samples were collected throughout the Thorn Project which is summarized in Table 3. The Top 10 gold-in-soils values ranged from 2,660 ppb Au to 16,750 ppb Au. The two highest gold-in-soil values were from the Metla Target returning 13,300 and 16,750 ppb Au respectively. The Outlaw Target had 6 soil samples in the Top 10 gold-in-soil values ranging from 2,660.0 ppb Au to 11,700.0 ppb Au.

The highest copper-in-soils came the East Target which was 3860 ppm Cu. Six of the Top 10 copper-in-soil values where from the East Target which ranged from 1860 ppm to 3860 ppm Cu.

The Outlaw Target generated the greatest number of gold-in-soils values. Anomalous gold-in-soil values of greater than 30 ppb Au from the 5588 samples was 1057 samples of which 500 were taken form the Outlaw Target, 273 were from the East Target, 220 were from the Metla Target, 19 from the West Target, 17 from the North Target, 9 from Trapper and 9 from Camp Creek. A total of 263 samples were greater than 100 ppb Au, of which 149 samples were from the Outlaw target. A total of 128 samples were greater than 200 ppb Au of which 76 were from the Outlaw Target. A total of 45 samples were greater than 500 ppb Au, of which 32 were from the Outlaw Target.

The Metla Target and East Target generated the greatest number of high copper-in-soil values. A total of 2298 samples from the 5588 collected were greater than 100 ppm Cu, of which 585 were from the Metla Target, 548 were from the East Target, 308 were from the Outlaw Target, 88 from the West Target, 48 were from the Trapper Target, 28 were from the North Target and 2 were from Camp Creek. A total of 148 samples returned greater than 500 ppm Cu of which 77 samples were from the East Target, 40 were from the Outlaw Target, 27 were from the Metla Target and 2 were from the West Target. A total of 40 samples were greater than 1000 ppm Cu of which 23 samples were from the East Target, 11 were from the Outlaw Target, 4 were from the Metla Target and 1 was from the West Target.

Click here for Table 3. Soil Geochemical Summary Results from 2020:

Prior to this season’s geochemical surveys, data mining of assessment reports and new property acquisitions the Thorn Project consisted of 3 targets, Camp Creek, Outlaw and Chivas. In addition to the Camp Creek Target, 3 new targets stand out as large scale copper targets: Metla, West Target and the East Target. The North and South Targets are of interest for copper as well but have had very limited sampling to date. The Figure 1 is a summary of all the data to date.

Click here for Figure 1. 2020 Copper Geochemistry and Compilation of Anomalous Data:

Two areas of interest stand out as gold dominate targets and they are the Trapper Gold Target and the Outlaw Gold Target. The Trapper Target is a NW-trending 7km long anomaly that consists of highly altered volcanic hosted zone with quartz stockwork-brecciation and visible sulphide mineralization. The Outlaw Target is a 4.3km east-west trending sediment hosted gold anomaly. Most targets contain both copper and gold, whereas the West Target is copper dominant (low gold), the Trapper and Outlaw are gold dominant (low copper).

Click here for Figure 2. 2020 Gold Geochemical Results and Complilation:

Brixton commissioned Fathom Geophysics to conduct a property-wide alteration mapping using ASTER and SENTINEL 2 satellite data. The satellite alteration footprint is showed in the figure 3 below along with the location of all targets.

Click here for Figure 3. Satellite Alteration Footprint of the Thorn Claim Block:

The Camp Creek Target

The copper-gold-silver mineralization within Camp Creek are of high-sulphidation veins containing pyrite, tetrahedrite, sulphosalts +- enargite where veins range from 0.1m to 5m meters in width, or breccia matrix filled sulphide/sulphosalts as diatreme or hydrothermal breccias. Copper results in Figure 4 are a complilation of all surface geochemical results for Camp Creek area. The Camp Creek Corridor has a minimum 2km long strike and has a series of northeast trending parallel veins-breccias over 1.5km wide that include the Talisker and Gelnfiddich zones. Thirty-five samples from Camp Creek area returned greater than 5% Cu with a high of 32.8% Cu. The Camp Creek target include the Oban diatreme polymetallic breccia which is about 100m in width having a north-south mineralized structure.

Click here for Figure 4. Camp Creek Copper Geochemistry:

The West Target

The West Target is a new area of interest which is dominantly copper (low gold). Including the 2020 soil and rock sampling, 14 rock samples returned greater than 1% Cu and a high of 4.3% Cu. Porphyry related veins with chalcopyrite, bornite, malachite and chalcocite were sampled at this target. An airborne radiometric and magnetic survey was flown at the West Target and revealed a large potassic-altered zone that encompasses the majority of the copper anomalies. Potassic alteration is known to occur at the center of large porphyry Cu-Au deposits.

Click here for Figure 5. West Target Copper Geochemical Compilation and Radiometrics Anomaly:

The Metla Target

The Metla Target was developed into a 20km Cu-Au anomaly by the strategic acquisition of the core lands held by Stuhini Exploration that came with significant previous work. The Figure 6 is focused on the compilation of copper values but the high gold values can be seen on Figure 2 and at the new release dated August 24, 2020 at the following link: . An airborne radiometric survey flow over the central Metla Target which highlights an open ended multi-kilometre potassic altered zone which corresponds well to the high copper numbers. Most of the 2020 sampling focused on the Eastern portion of the Metla Target area where 11 rock samples returned greater than 1% Cu with a high of 3.4% Cu. The total number of copper values greater that 1% from the Central and East Metla combined are 36 with the highest copper value of 15.2% Cu from the Central Metla Target area. Mineralization is porphyry related with chalcopyrite, bornite, chalcocite and malachite/azurite.

Click here for Figures 6. Metla Target Copper Geochemical Compilation and Radiometric Anomaly:

The East Target

One of the new target this season is the East Target which is located on the East edge of the Thorn property. Twenty-two rock samples were greater than 1% Cu with a high of 5.2% Cu. Two large multi-kilometer copper-in-soil anomalies were identified on the East Target.

Click here for Figure 7. East Target Copper Geochemical Rocks over Soils and Alteration:

The South Target

Geochemical surveying at the South Target was limited given that other targets were prioritized, with only one rock sample of 1.5% Cu. However, the size of the alteration footprint at this target is remarkable (i.e. 20km x 20km) and worthy to follow-up with subsequent geochemical surveys and prospecting/mapping.

Click here for Figure 8. South Target Copper Rock and Soil Geochemical over Alteration.

The Trapper Target

The Trapper Target returned the highest number of gold anomalies in rocks, with 26 samples greater that 1 g/t Au, 10 samples greater than 5 g/t Au, 6 samples greater than 10 g/t Au including 4 samples greater than 31.0 g/t Au, with one of 47 g/t Au. Please see more details from a previously released news about the Trapper Target gold samples:

The Trapper Gold trend is a NW-SE striking, 7km long gold trend which resulted from the strategic acquisition of the Trapper claims from Kodiak Copper earlier this year, see news and details at the following link.

In 2017 Brixton drilled hole THN17-142 which returned 6.4m of 2.8 g/t Au and is located at the Chivas Target located in the northern portion of the Trapper Gold Trend characterized by a large gold-in-soils anomaly.

Click here for Figure 9. Trapper Gold Target, Gold Geochemistry:

The Outlaw Target

The Outlaw Target generated a high number of gold-in-soil and gold-in-rock samples this season. Details of 2020 drilling can be seen at the following links:

Click here for Figure 10. Outlaw Soil and Rock Geochemistry:


Soil and rock geochemistry has proven to be an effective tool in targeting mineralization at the Thorn Project. High priority targets include Trapper, Metla, Outlaw, Camp Creek. Secondarily, but also of interest, are the East and West Targets. Drill-ready targets for 2021 include Trapper, Metla, Outlaw and Camp Creek.

Mr. Antonio Celis, MSc., P.Geo., who is a qualified person as defined by National Instrument 43-101, reviewed and approved the information in this press release.

About Brixton Metals Corporation

Brixton is a Canadian exploration and development company focused on the advancement of its gold, copper and silver projects toward feasibility. Brixton wholly owns four exploration projects, the Thorn copper-gold-silver and the Atlin Goldfields Projects located in NWBC with a combined total of 3600sqkm of mineral tenure, the past producing Langis-HudBay silver-cobalt brownfield projects in Ontario and the past producing advanced stage Hog Heaven silver-gold-copper project in NW Montana, USA. Brixton Metals Corporation shares trade on the TSX-V under the ticker symbol BBB and in the USA OTCQB market under the ticker symbol BBBXF. For more information about Brixton please visit our website at

On Behalf of the Board of Directors

Mr. Gary R. Thompson, P.Geo., Chairman and CEO
Tel: 604-630-9707 or email: [email protected]

For Investor Relations please contact Mitchell Smith, VP of Investor Relations
Tel: 604-630-9707 or email: [email protected]

Cautionary Note

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Information set forth in this news release may involve forward-looking statements under applicable securities laws. Forward-looking statements are statements that relate to future, not past, events. In this context, forward-looking statements often address expected future business and financial performance, and often contain words such as “anticipate”, “believe”, “plan”, “estimate”, “expect”, and “intend”, statements that an action or event “may”, “might”, “could”, “should”, or “will” be taken or occur, including statements that address potential quantity and/or grade of minerals, potential size and expansion of a mineralized zone, proposed timing of exploration and development plans, or other similar expressions. All statements, other than statements of historical fact included herein including, without limitation, statements regarding the use of proceeds, the closing date of the Private Placement, the expenditures and cash payments to be made by HPX and the negotiation and execution of definitive agreements by HPX and Brixton are forward looking statements. By their nature, forward-looking statements involve known and unknown risks and uncertainties which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, among others, the following risks: the need for additional financing; operational risks associated with mineral exploration; fluctuations in commodity prices; title matters; and the additional risks identified in the annual information form of the Company or other reports and filings with the Exchange and applicable Canadian securities regulators. Forward-looking statements are made based on management’s beliefs, estimates and opinions on the date that statements are made and the Company undertakes no obligation to update forward-looking statements if these beliefs, estimates and opinions or other circumstances should change, except as required by applicable securities laws. Investors are cautioned against attributing undue certainty to forward-looking statement.

Photos accompanying this announcement are available at: 

Enzo Biochem Hosting Key Opinion Leader Call on GENFLEX™ Molecular System for COVID-19 and the Role of Testing in a Post-Vaccine Treatment Environment

Thursday, December 17th @ 12:00pmET

New York, NY, Dec. 15, 2020 (GLOBE NEWSWIRE) — Enzo Biochem, Inc. (NYSE:ENZ), a leading biosciences and diagnostics company, today announced that it will host a key opinion leader (KOL) webinar discussing the use of the GENFLEX™ Molecular System for COVID-19 testing and the role of testing in a post-vaccine treatment environment, on Thursday, December 17, 2020 at 12:00pm Eastern Time.

Infectious disease specialists Bruce Hanna, PhD, NYU Grossman School of Medicine, and Gerard Nuovo, MD, Ohio State University College of Medicine, will discuss the GENFLEX™ Molecular System for COVID-19 and the role of testing in a post-vaccine treatment environment. Included in this discussion will be the advantages of Enzyme-Linked Immunosorbent Assay (ELISA) kit technology for COVID-19 related serological testing. Drs. Hanna and Nuovo will be available to answer questions following the formal presentations. 

Enzo Biochem’s management team will also give an update on the applications of GENFLEX™ Molecular System and ELISA kit testing platforms as access to vaccines expands in 2021. The GENFLEX™ Molecular System, which received FDA Emergency Use Authorization (EUA), is an all-in-one solution for COVID-19 molecular testing from extraction, detection and analysis to clinical results. The ELISA kit is designed for the qualitative detection of IgG antibodies specific to COVID-19 in human serum samples. Enzo’s serological solutions aid in identifying individuals with an adaptive immune response to COVID-19.

To register for the call, please click here.

Bruce Hanna, PhD, has served as a Clinical Professor of Pathology and Clinical Professor of Microbiology at the New York University School of Medicine since 1979 and Adjunct Professor of Science at New York University College of Dentistry since 2010. From 2006 to 2015, he served on the ASM International Committee and WHO Global Committee; from 2000 to 2012, he served as the Editor of the Clinical Microbiology Review; from 1982 to 2010, he was a director of Clinical Microbiology and Immunology; and from 2008 to 2010 he was Interim director of Pathology, Bellevue Hospital Center. Dr. Hanna earned a Bachelor of Science in Biology from Saint Bonaventure University, a Masters in Science in Microbiology from Northeastern University and a Ph.D. in Microbiology from Saint John’s University. Dr. Hanna’s post-doctorate work in Clinical Microbiology was at Mt. Sinai Hospital.

Dr. Gerard Nuovo is a board-certified anatomic  pathologist and has spent his entire 30+ year career correlating the histologic features with the in situ detection of DNA, RNA, and proteins. He currently is medical director of a Molecular Pathology Laboratory (Phylogeny) that serves as a satellite laboratory for the OSUCCC. His group has invented several methodologies that can be used for the enhanced in situ detection of mRNA, viral nucleic acids, and microRNAs, including RT in situ PCR and the ultramer extension method for the latter. Further, he has extensive experience with the in situ co-localization of RNA/DNA molecules and proteins. He has published over 333 peer review manuscripts, written 6 textbooks, has done over 40 invited chapters, and has been a co-PI on over 20 grants. His group was the first to show that human papillomavirus induced a type specific immunity and was one of the first groups to show that HIV-1 caused a massive infection prior to the development of AIDS. He has done extensive work on the molecular events that underlie the use of viruses as oncolytic agents in cancer.

About Enzo Biochem

, Inc.

Enzo Biochem is a pioneer in molecular diagnostics, leading the convergence of clinical laboratories, life sciences and intellectual property through the development of unique diagnostic platform technologies that provide numerous advantages over previous standards. A global company, Enzo Biochem utilizes cross-functional teams to develop and deploy products, systems and services that meet the ever-changing and rapidly growing needs of health care today and into the future. Underpinning Enzo Biochem’s products and technologies is a broad and deep intellectual property portfolio, with 475 issued patents worldwide along with extensive enabling technologies and platforms. 

Forward-Looking Statements

Except for historical information, the matters discussed in this news release may be considered “forward-looking” statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements include declarations regarding the intent, belief or current expectations of the Company and its management, including those related to cash flow, gross margins, revenue, and expenses which are dependent on a number of factors outside of the control of the Company including, inter alia, the markets for the Company’s products and services, costs of goods and services, other expenses, government regulations, litigation, and general business conditions. See Risk Factors in the Company’s Form 10-K for the fiscal year ended July 31, 2019 and Form 10-Q for the period ended July 31, 2020. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve a number of risks and uncertainties that could materially affect actual results. The Company disclaims any obligations to update any forward-looking statement as a result of developments occurring after the date of this press release.

Enzo Biochem, Inc.
David Bench, CFO
[email protected] 

LifeSci Advisors, LLC
Jeremy Feffer
[email protected] 

Julia Otey-Raudes, CEO of Eco Innovation Group, Inc., is Featured in a New Audio Interview with

Interview provides insights and excitement surrounding their inventors and innovations, competitive strengths, and overall company performance in 2020

AUSTIN, Texas, Dec. 15, 2020 (GLOBE NEWSWIRE) —, Inc. (“SCV”) today announced the availability of a recent interview with the leadership of Eco Innovation Group, Inc. (OTC: ECOX) (the “Company”), an innovative company aggregating investments in new technologies that promote environmental and social well-being, and the advancement of green energy solutions. The interview outlines the development of ECOX’s portfolio of technology assets, the evolution of the Company to date, and the goals for the remainder of 2020 and beyond.

Speaking with SCV’s Stuart Smith, Otey-Raudes explains the genesis and story behind the recent moves by ECOX and the foundation built in 2020. In 2020, amidst a global pandemic, the Company was able to make key strategic moves fortifying ECOX for future growth and expansion. The Company was able to complete a two-year audit with a PCAOB registered audit firm as part of filing an S1 registration statement, all the while maintaining very lean overhead with a minimal burn rate.

When asked about her team at Eco Innovation Group, Otey-Raudes tells Smith, “Our people really make me proud. I have worked for the last 10 years in the renewable energy field. I was able to meet some amazing people that have joined us in Eco Innovation Group. I am proud that most funds for the company have been raised by equity or sales generated by the company and we have been able to avoid the typical toxic lender situations.” Ms. Otey-Raudes added, “The Company is ideally positioned for scale and growth. We are thankful for the opportunity to share our story with our shareholders and the listening audience.”

The full interview can be heard at:

About Eco Innovation Group

Eco Innovation Group was founded by inventors and business professionals to help nurture and catalyze the most innovative and impactful products and services, and to deliver those innovations to the world, improving the quality of life in our communities and the world around us, while delivering value to our shareholders. At ECOX, we are dedicated to developing and commercializing successful products. But we will never lose sight of the fact that we exist, first and foremost, to help people and improve life on the planet we all share. We take our Social Responsibility Contract seriously in all our endeavors. It is not only what we do. It is who we are. For more information, visit

About SmallCapVoice, Inc. is a recognized corporate investor relations firm, with clients nationwide, known for its ability to help emerging growth companies, small cap and micro-cap stocks build a following among retail and institutional investors. utilizes its stock newsletter to feature its daily stock picks, podcasts, as well as its clients’ financial news releases. also offers individual investors all the tools they need to make informed decisions about the stocks in which they are interested. Tools like stock charts, stock alerts, and Company Information Sheets can assist with investing in stocks that are traded on the OTCMarkets. To learn more about and its services, please visit

Socialize with SmallCapVoice and their clients at


FORWARD-LOOKING STATEMENTS: This release contains “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements also may be included in other publicly available documents issued by the Company and in oral statements made by our officers and representatives from time to time. These forward-looking statements are intended to provide management’s current expectations or plans for our future operating and financial performance, based on assumptions currently believed to be valid. They can be identified by the use of words such as “anticipate,” “intend,” “plan,” “goal,” “seek,” “believe,” “project,” “estimate,” “expect,” “strategy,” “future,” “likely,” “may,” “should,” “would,” “could,” “will” and other words of similar meaning in connection with a discussion of future operating or financial performance. Examples of forward-looking statements include, among others, statements relating to future sales, earnings, cash flows, results of operations, uses of cash and other measures of financial performance.

Because forward-looking statements relate to the future, they are subject to inherent risks, uncertainties and other factors that may cause the Company’s actual results and financial condition to differ materially from those expressed or implied in the forward-looking statements. Such risks, uncertainties and other factors include, among others such as, but not limited to economic conditions, changes in the laws or regulations, demand for products and services of the company, the effects of competition and other factors that could cause actual results to differ materially from those projected or represented in the forward-looking statements. Any forward-looking information provided in this release should be considered with these factors in mind. We assume no obligation to update any forward-looking statements contained in this report.

Corporate Contact:

Eco Innovation Group, Inc.
[email protected] Contact:

Stuart T. Smith
[email protected]


Immutep Operational Update

  • Efti clinical trial status updates
  • Excellent financial position following recent US$7.7 million warrant exercise, with cash runway extended beyond end of calendar year 2022

Sydney, AUSTRALIA, Dec. 15, 2020 (GLOBE NEWSWIRE) —  Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune disease, provides an update on efti clinical programs.

Eftilagimod alpha (“efti”) Update

AIPAC – Phase IIb clinical trial

The Company presented in a spotlight presentation at the San Antonio Breast Cancer Symposium 2020, first Overall Survival (OS) data and is on track to report final overall survival data and overall response rate by mid calendar year 2021. Currently there are more than 66% of events compared to approx. 60% which were the basis of the OS data presented at the San Antonio Breast Cancer Conference.

TACTI-002 – Phase II clinical trial

The 3rd stage of 1st line NSCLC with an additional 74 patients in the US, Australia and Europe is now open for recruitment. The TACTI-002 Phase II study, which is being conducted in collaboration with Merck & Co., Inc., Kenilworth, NJ, USA (known as “MSD” outside the United States and Canada), has been expanded by 74 additional patients, following the results presented at SITC in November 2020.

Recruitment is ongoing for stage 2 of Part C (second line head and neck squamous cell carcinoma) and it is expected to open recruitment of stage 2 of Part B (second line non-small cell lung cancer) in the next year.

Phase II Clinical Trial in Head and Neck Cancer

Immutep continues to prepare for a new randomised, controlled Phase II clinical study in approximately 160 1st line HNSCC patients. Patients will be 1:1 randomised to receive efti in combination with an anti-PD-1 treatment, or anti-PD-1 monotherapy. The trial is intended to take place across clinical trial sites in the United States, Australia and Europe.

TACTI-mel – Phase I clinical trial

The results of Immutep’s Phase I TACTI-mel trial were recently published in the Journal for ImmunoTherapy of Cancer. The trial was conducted in Australia and evaluated efti in combination with pembrolizumab in metastatic melanoma.

INSIGHT-004 – Phase I clinical trial

INSIGHT-004, the fourth arm of the INSIGHT trial (INSIGHT-004 is also known as Stratum D of INSIGHT) which is being conducted in collaboration with Merck KGaA, Darmstadt, Germany and Pfizer Inc. is expected to deliver final data in 2021. First data from the study were presented at ASCO and ESMO 2020.

EOC Pharma – Phase II clinical trial

Preparations are ongoing for a new Phase II clinical study in China (152 patients) evaluating efti in combination with chemotherapy for the treatment of metastatic breast cancer.

Financial Update

In the current quarter, Immutep completed an equity financing and raised approximately A$29.6 million in a placement supported by high quality institutional investors from Australia and offshore.

In addition, given the recent exercise of warrants over American Depository Shares, which generated proceeds of approximately US$7.7 million (approx. AU$10.1 million), the Company is in an excellent financial position with a cash runway beyond end of calendar year 2022.

About Immutep

Immutep is a globally active biotechnology company that is a leader in the development of LAG-3 related immunotherapeutic products for the treatment of cancer and autoimmune disease. Immutep is dedicated to leveraging its technology and expertise to bring innovative treatment options to market for patients and to maximize value to shareholders. Immutep is listed on the Australian Securities Exchange (IMM), and on the NASDAQ (IMMP) in the United States.

Immutep’s current lead product candidate is eftilagimod alpha (“efti” or “IMP321”), a soluble LAG-3 fusion protein (LAG-3Ig), which is a first-in-class antigen presenting cell (APC) activator being explored in cancer and infectious disease. Immutep is also developing an agonist of LAG-3 (IMP761) for autoimmune disease. Additional LAG-3 products, including antibodies for immune response modulation, are being developed by Immutep’s large pharmaceutical partners.

Further information can be found on the Company’s website or by contacting:

Australian Investors/Media:

Catherine Strong, Citadel-MAGNUS
+61 (0)406 759 268; [email protected]

U.S. Media:

Tim McCarthy, LifeSci Advisors
+1 (212) 915.2564; [email protected]

Badger Daylighting Ltd. December 2020 Cash Dividend

CALGARY, Alberta, Dec. 15, 2020 (GLOBE NEWSWIRE) — Badger Daylighting Ltd. (“Badger”) is pleased to announce its December 2020 cash dividend.

December 2020 Cash Dividend

Badger today announced that the directors of Badger declared a cash dividend for the month of December 2020 of $0.05 per share, which equates to $0.60 per share on an annualized basis. Payment will be made on or about January 15, 2021, to shareholders of record on December 31, 2020.

Badger expects that the dividend will be an “eligible dividend” for Canadian income tax purposes and thus qualify for the enhanced gross-up and tax credit regime for certain shareholders.

About Badger Daylighting Ltd.

Badger Daylighting Ltd. (TSX:BAD) is North America’s largest provider of non-destructive excavating services. Badger traditionally works for contractors and facility owners in a broad range of infrastructure industries. The Company’s key technology is the Badger Hydrovac, which is used primarily for safe digging in congested grounds and challenging conditions. The Badger Hydrovac uses a pressurized water stream to liquefy the soil cover, which is then removed with a powerful vacuum system and deposited into a storage tank. Badger manufactures its truck-mounted hydrovac units.


Paul Vanderberg, Presidentand CEO
Darren Yaworsky, Vice President, Finance and CFO
Pramod Bhatia, Vice President, Strategic Planning and Investor Relations

Badger Daylighting Ltd.

ATCO Centre Ⅱ
Suite 400, 919 – 11th Avenue SW
Calgary, Alberta T2R 1P3
Telephone (403) 264-8500
Fax (403) 228-9773

Source: Badger Daylighting Ltd.

Pinduoduo named digital agriculture pioneer at 2020 World Digital Agriculture Conference

SHANGHAI, China, Dec. 15, 2020 (GLOBE NEWSWIRE) — Pinduoduo Inc. (NASDAQ: PDD), China’s largest agri-focused technology platform, was named a pioneer in digital agriculture at a major conference, with its “cloud agriculture” model recognized as one of the top 10 achievements in digital agriculture in the world.

The accolades were handed out at the 2020 World Digital Agriculture Conference held in Guangzhou, China, on Dec. 12. The conference aims to demonstrate the integration of digital technology and modern agriculture, and the organizing committee selected several case studies to showcase how digital technology empowers agriculture.

Pinduoduo has focused on agriculture since its establishment in 2015 and has become the go-to destination for high quality, great value agricultural products. In 2019, the transaction volume of farm products reached RMB 136.4 billion (US$20.8 billion) on Pinduoduo’s online marketplace.

As of the end of 2019, Pinduoduo has covered almost all agricultural production areas in China, with more than 12 million agrarian producers directly connected to the marketplace serving more than 700 million consumers.

Pinduoduo has brought a systems approach to tackling the inter-related issues at various points of the agricultural value chain, committing substantial resources and investments to solve entrenched structural problems in the industry.

The company’s initiatives include improving downstream market access for farmers and training younger e-commerce talent, revamping midstream logistics infrastructure to reduce waste, lower costs and speed up the delivery of agricultural products. Pinduoduo also works with industry partners and universities to develop upstream technology to increase the resilience of the food supply chain.

Earlier this year, Pinduoduo jointly organized the Smart Agriculture Competition with the China Agricultural University, under the technical guidance of the Food and Agriculture Organization of the United Nations. The competition sought to identify cost-efficient and scalable agricultural technology that can be promoted as standardized solutions across China. The final results are expected to be released on Dec. 16, 2020.

About Pinduoduo Inc.

Pinduoduo is an innovative and fast-growing technology platform that provides buyers with value-for-money merchandise and fun and interactive shopping experiences. The Pinduoduo mobile platform offers a comprehensive selection of attractively priced merchandise, featuring a dynamic social shopping experience that leverages social networks effectively.

For more information on Pinduoduo news and industry trends, please visit our content hub at

For media enquiries, please contact us at [email protected]

Philadelphia Eagles Reach Multi-Year Deal with Esports Entertainment Group to Become NFL’s First Esports Tournament Club Provider

NEWARK, N.J., Dec. 15, 2020 (GLOBE NEWSWIRE) — Esports Entertainment Group, Inc. (NasdaqCM: GMBL, GMBLW) (or the “Company”) has announced a landmark multi-year partnership with the Philadelphia Eagles where it will serve as the first esports tournament provider for an NFL club. As part of the multi-year agreement, EEG will operate bi-annual Madden NFL esports tournaments for the Eagles utilizing the Esports Gaming League (“EGL”) platform. Also under the terms of the deal, the Eagles will become an EEG shareholder.

“We are thrilled to partner with the Philadelphia Eagles as they introduce their fans to the world of competitive esports gaming,” said Grant Johnson, CEO of Esports Entertainment Group. “The Eagles join a growing list of high-profile organizations that have chosen Esports Entertainment Group as their esports tournament provider, affording us an incredible opportunity to expand our brand reach within multiple large, dedicated fan bases and setting the stage for significant growth ahead. We intend to build on this momentum.”

As a proud partner of the Philadelphia Eagles, EEG will leverage player imagery within the Eagles local market. Esports Entertainment Group will also work with Eagles players to create custom videos that will promote the tournaments and be featured in the Eagles extensive ongoing digital marketing efforts spanning social, email, mobile, and online channels.

“This innovative partnership with Esports Entertainment Group presents a wonderful opportunity for us to expand our reach in a growing market and create new experiences for Eagles fans,” said Catherine Carlson, Senior Vice President, Revenue and Strategy, Philadelphia Eagles. “Esports Entertainment Group has always been a progressive leader in the esports space and has been ahead of the curve in terms of how its interactive platform brings together gaming enthusiasts from all around the world. We look forward to debuting a number of exciting projects through this partnership, including the launch of the highly anticipated Madden tournament series on the Esports Gaming League platform.”

“Our tournament segment is a key component of our Three Pillar growth strategy,” said Magnus Leppäniemi, EVP Esports at EEG. “This partnership with the Philadelphia Eagles is a testament to the quality of our platform and ability to deliver. We look forward to a long and mutually rewarding relationship.”

EGL enables live and online events and tournaments where gamers can compete and enjoy a wide range of content relating to esports and video games on a proprietary technology platform. Services include full turnkey esports events, live broadcast production, game launches, and online branded tournaments.

About Esports Entertainment Group

Esports Entertainment Group, Inc. is a licensed online gambling company with a specific focus on esports wagering and 18+ gaming. Esports Entertainment offers fixed odds wagering, fantasy and pools on various esports events in a licensed, regulated and secure platform at and owns and operates online sports book, In addition, Esports Entertainment intends to offer users from around the world the ability to participate in multiplayer mobile and PC video game tournaments for cash prizes. Esports Entertainment is led by a team of industry professionals and technical experts from the online gambling and the video game industries, and esports. The Company holds a license to conduct online gambling and 18+ gaming on a global basis in the UK, Ireland, Malta and Curacao. The Company maintains offices in New Jersey, the UK and Malta. For more information visit


The information contained herein includes forward-looking statements. These statements relate to future events or to our future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond our control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects our current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to our operations, results of operations, growth strategy and liquidity. We assume no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. The safe harbor for forward-looking statements contained in the Securities Litigation Reform Act of 1995 protects companies from liability for their forward-looking statements if they comply with the requirements of the Act.


U.S. Investor Relations 
RedChip Companies, Inc.
Dave Gentry
[email protected]

Media & Investor Relations Inquiries

[email protected]

Secure Technology Alliance and U.S. Payments Forum Name Jason Bohrer as New Director

Succeeds retiring 18-year director Randy Vanderhoof

PRINCETON JUNCTION, N.J., Dec. 15, 2020 (GLOBE NEWSWIRE) — The Secure Technology Alliance and U.S. Payments Forum today announced Jason Bohrer as the new executive director of both organizations. Bohrer brings 27 years of executive leadership experience in sales, operations and managed services. His impressive record of achievements spans payments, access control and identity management at CPI Card Group, HID Global and Motorola. Bohrer is well positioned to help both organizations advance their missions to accelerate the adoption of technologies and solutions that provide speed, convenience and security in an increasingly digital world.

“The Secure Technology Alliance and the U.S. Payments Forum are the go-to organizations for collaboration, education, best practices and guidance in the security and payments technology industries,” said Bohrer. “I am thrilled to have the opportunity to support these organizations and their wide-reaching initiatives, and I look forward to building upon the great work that was already done under Randy Vanderhoof’s leadership. Looking ahead, rapid changes in payments, security, mobile ID services, IoT, and transit fare collection technologies and solutions will continue, and these two organizations will be at the forefront of the transformation and implementation of those businesses. There is much to do and I’m excited to kick off 2021 in this new role.”

Bohrer succeeds retiring Randy Vanderhoof, whose career as executive director of the Smart Card Alliance began in 2002 when smart cards were virtually unknown in the U.S. The organization scored rapid successes under Vanderhoof’s stewardship, including working with government agencies and technology providers to implement Personal Identity Verification (PIV) cards as a common government-wide identity credential. Soon after, the organization helped standardize contactless smart card technology for U.S. electronic passports. The crowning achievement came in 2012, when after years of effort, the Alliance led the conversion of the entire U.S. payments industry to chip cards through the creation of the EMV Migration Forum, now the U.S. Payments Forum. This record of accomplishment testifies to Vanderhoof’s legacy as a visionary leader and the organizations’ collaborative successes in realizing these complex business and technology implementations.

Both organizations are moving into 2021 with tremendous momentum and new member-led projects and initiatives. These activities align with industry-driven priorities and provide guidance to help their industries evolve efficiently and securely.

“The Alliance has been an influential force to help drive national markets toward more secure and convenient technologies,” said Oliver Manahan, co-chair of the Alliance’s Board of Directors. “As we shift our focus to technologies that enable new applications like mobile driver’s licenses and Mobility-as-a-Service, Jason’s fresh insights and energy will be extremely valuable, and we look forward to changing the world together.”

“We are coming out of a year of rapid change in consumer shopping and payment preferences, and the Forum is looking forward to continuing to provide guidance and best practices to the industry for 2021,” said Kristy Cook, chair of the U.S. Payments Forum Steering Committee. “Jason brings extensive leadership experience, payment insight and an appreciation for the diversity of payment stakeholders to the role, and we’re excited to have him leading the Forum as we foster emerging payments and technologies into the U.S. market.”

About the Secure Technology Alliance

The Secure Technology Alliance is the digital security industry’s premier association. The Alliance brings together leading providers and adopters of end-to-end security solutions designed to protect privacy and digital assets in payments, mobile, identity and access, healthcare, transportation and the emerging Internet of Things (IoT) markets.

The Alliance’s mission is to stimulate understanding, adoption and widespread application of connected digital solutions based on secure chip and other technologies and systems needed to protect data, enable secure authentication and facilitate commerce.

The Alliance is driven by its U.S.-focused member companies. They collaborate by sharing expertise and industry best practices through industry and technology councils, focused events, educational resources, industry outreach, advocacy, training and certification programs. Through participation in the breadth of Alliance activities, members strengthen personal and organizational networks and take away the insights to build the business strategies needed to commercialize secure products and services in this dynamic environment.

For more information, please visit

About the U.S. Payments Forum

The U.S. Payments Forum is a cross-industry body focused on supporting the introduction and implementation of new and emerging technologies that protect the security of, and enhance opportunities for payment transactions within the U.S. The Forum is the only non-profit organization whose membership includes the whole payments ecosystem, ensuring that all stakeholders have the opportunity to coordinate, cooperate on, and have a voice in the future of the U.S. payments industry.

For more information, please visit


Adrian Loth and Dana Kringel
Montner Tech PR
[email protected]
[email protected] 

Cidara Therapeutics Appoints Biotechnology Industry Veteran Christopher Kurtz As Executive Vice President of Technical Operations

Former head of commercial API manufacturing at Gilead Sciences will lead technical operations for development of Cidara’s antifungal and antiviral programs

SAN DIEGO, Dec. 15, 2020 (GLOBE NEWSWIRE) — Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today announced the appointment of Christopher (Chris) Kurtz as executive vice president of technical operations. Mr. Kurtz brings more than 26 years of experience in global manufacturing, engineering, supply chain, CMC development and program management for drugs and devices at various stages of development.

“We are pleased to welcome Chris to our leadership team at such a pivotal time for our antifungal and antiviral programs,” said Jeffrey Stein, Ph.D., president and chief executive officer of Cidara. “Chris’s leadership and deep manufacturing expertise, delivering both biologic and small molecule drugs to market, will be invaluable as we advance rezafungin, currently in pivotal Phase 3 trials, towards filing, and advance our antiviral conjugate (AVC) influenza program to IND filing.”

Prior to joining Cidara, Mr. Kurtz served as head of commercial API manufacturing at Gilead Sciences, where he and his team played an instrumental role in the recent launches of products such as Biktarvy and Veklury (remdesivir). He previously served as vice president, for drug device industrialization at AbbVie, where he led product scale-up and industrialization projects for drug-device combinations. Prior to that, Mr. Kurtz held a number of leadership positions where he managed the development, scale-up and commercialization of drugs, biologics, medical devices and combination products at various companies, including Monsanto, Nektar Therapeutics, Alza Corporation, Alexza and Novo Nordisk. He has successfully established supply capabilities and navigated products from late-stage development through approval, launch and sustained commercialization. Mr. Kurtz holds a B.S. in chemical engineering from the University of Colorado and is a graduate of the Westinghouse S3G Nuclear Engineering Program. He is also a proud veteran of the US Navy Submarine Force.

Mr. Kurtz commented, “Cidara’s commitment to the development of novel long-acting therapeutics for serious fungal and viral infections is of vital importance now more than ever. Rezafungin has the potential to become the new standard of care for the treatment and prevention of invasive fungal infections globally, and I look forward to leveraging my manufacturing and supply chain expertise to support a successful launch in the coming years. Additionally, Cidara is leveraging its Cloudbreak platform to create a new class of long-acting antivirals in influenza, RSV and HIV, and I am very excited to work with the Cidara team to advance these programs.”

About Rezafungin

Rezafungin is a novel once-weekly echinocandin being developed for both the treatment and prevention of serious fungal infections, such as candidemia and invasive candidiasis. The structure and properties of rezafungin are specifically designed to improve upon a clinically validated mechanism intended to enhance its efficacy and safety potential for patients. Cidara is currently conducting a Phase 3 clinical trial with rezafungin for the first-line treatment of candidemia and/or invasive candidiasis (ReSTORE trial) and a second Phase 3 clinical trial of once-weekly rezafungin for the prevention of invasive fungal disease in patients undergoing allogeneic blood and marrow transplantation (ReSPECT trial).

About Cloudbreak AVCs

Cidara is developing a new generation of immunotherapeutic antivirals from its Cloudbreak antiviral platform that couple potent antivirals to a human antibody fragment. These long-acting, antiviral conjugates (AVCs) directly inhibit viral proliferation while simultaneously engaging the immune system. AVCs are initially being studied for the prevention and treatment of seasonal and pandemic influenza, with the potential to deliver universal protection for an entire flu season with a single dose. Cidara is also advancing preclinical and discovery AVC programs to target other life-threatening viruses, such as RSV, HIV and CoV, including COVID-19.

About Cidara Therapeutics

Cidara is developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections. The Company’s portfolio is comprised of its lead antifungal candidate, rezafungin, in addition to antiviral conjugates (AVCs) for the prevention and treatment of influenza and other viral diseases from Cidara’s proprietary Cloudbreak® antiviral platform. Cidara is headquartered in San Diego, California. For more information, please visit

Forward-Looking Statements

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “anticipates,” “expect,” “may,” “plan” or “will”. Forward-looking statements in this release include, but are not limited to, statements related to the potential for rezafungin to transform the standard of care in treatment and prevention of invasive fungal infections, as well as the potential of the Cloudbreak platform to create a new class of long-acting AVCs in influenza, RSV and HIV. Such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, such as unanticipated delays in or negative results from Cidara’s clinical trials, impacts of the COVID-19 pandemic on patient enrollment or other obstacles to the development of rezafungin and advancement of Cidara’s other development programs. These and other risks are identified under the caption “Risk Factors” in Cidara’s most recent Quarterly Report on Form 10-Q and other filings subsequently made with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management’s assumptions and estimates as of such date. Cidara does not undertake any obligation to publicly update any forward-looking statements, whether as a result of the receipt of new information, the occurrence of future events or otherwise.


Brian Ritchie
LifeSci Advisors
(212) 915-2578
[email protected]


Karen O’Shea, Ph.D.
LifeSci Communications
(929) 469-3860
[email protected]